1-7 of 7
Samantha Pazienza
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Free
Austin Kim, Peter Riedell, Christine Ryan, Robert Redd, Clare Phinney, Juniper Mai, Samantha Pazienza, Caitlin Bravo, Vanessa Kats, Salah Abdulkarim, Susan Waisgerber, Reid Merryman, David Fisher, Inhye Ahn, Jennifer Crombie, Oreofe Odejide, Ann LaCasce, Caron Jacobson, Eric Jacobsen, Erin Parry, David Qualls, Amy Bessnow, Matthew S Davids, Jennifer Brown, Jon Arnason, Michael Leukam, Philippe Armand, Justin Kline, Mark Murakami
Journal: Blood
Blood (2025) 146 (Supplement 1): 664.
https://doi.org/10.1182/blood-2025-664
Published: 2025
Journal Articles

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Free
Jennifer Brown, Robert Black, Hang Phan, Katherine Chapis, Samantha Pazienza, Sandra Re, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Lars van der Veen, Michael Lahn, Philippe Armand
Journal: Blood
Blood (2025) 146 (Supplement 1): 3913.
https://doi.org/10.1182/blood-2025-3913
Published: 2025
Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Free
Austin I. Kim, Philippe Armand, Christine E. Ryan, Robert A. Redd, Megan Forsyth, Juniper Mai, Samantha Pazienza, Caitlin Bresnahan, Vanessa M Kats, Salah Abdulkarim, Susan M Waisgerber, Reid W. Merryman, David C. Fisher, Inhye E. Ahn, Jennifer L. Crombie, Oreofe O. Odejide, Ann S. LaCasce, Caron A. Jacobson, Eric D. Jacobsen, Erin M. Parry, David A. Qualls, Amy C. Bessnow, Matthew S. Davids, Jennifer R. Brown, Jon E. Arnason, Michael Leukam, Peter A. Riedell, Mark A. Murakami
Journal: Blood
Blood (2024) 144 (Supplement 1): 4408.
https://doi.org/10.1182/blood-2024-198056
Published: 2024
Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Free
Austin I Kim, Philippe Armand, Robert A. Redd, Megan Forsyth, Paul Branch, Samantha Pazienza, Lisa Brennan, Victoria Patterson, Susan M Waisgerber, Reid W. Merryman, David C Fisher, Christine E. Ryan, Inhye E Ahn, Jennifer L Crombie, Oreofe O. Odejide, Ann LaCasce, Caron A Jacobson, Eric Jacobsen, Erin M Parry, Matthew S Davids, Jennifer R. Brown, Arnold S. Freedman, Peter A. Riedell, Mark Alan Murakami
Journal: Blood
Blood (2023) 142 (Supplement 1): 3031.
https://doi.org/10.1182/blood-2023-173103
Published: 2023
Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Free
Christine E. Ryan, Benjamin L. Lampson, Svitlana Tyekucheva, Liam R. Hackett, Yue Ren, Samantha J. Shupe, Stacey M. Fernandes, Jennifer L. Crombie, Samuel Ng, Austin I. Kim, Inhye E. Ahn, Matthew J Weinstock, Samantha Pazienza, Josie S. Montegaard, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Jon E. Arnason, Steve Lo, Adam Olszewski, Jennifer R. Brown, Matthew S. Davids
Journal: Blood
Blood (2022) 140 (Supplement 1): 837–838.
https://doi.org/10.1182/blood-2022-168003
Published: 2022
Journal Articles

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Free
Clinical Trials & Observations Brief Report
Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Sarah K. Renner, Josie Montegaard, Udochukwu Ihuoma, Timothy Z. Lehmberg, Erin M. Parry, Catherine J. Wu, Caron A. Jacobson, David C. Fisher, Philip A. Thompson, Jennifer R. Brown
Journal: Blood
Blood (2022) 139 (5): 686–689.
https://doi.org/10.1182/blood.2021011386
Published: 2022
Includes: Supplemental data
Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Free
Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139864
Published: 2020